Octreotide Pamoate
Kidney Failure, Acute
University of California, Los AngelesPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
21 Active assets in the Kidney Failure, Acute cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Giapreza The Cleveland Clinic | Phase 4 | BB |
Everolimus MARIO ABBUD FILHO | Phase 4 | B |
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)- Tanta University | Phase 4 | B |
PROPRANOLOL Taipei Veterans General Hospital, Taiwan | Phase 4 | B |
Noradrenaline University of California, Los Angeles | Phase 4 | B |
View all 32 →
Same molecule, other indications
Octreotide Pamoate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →